Vanguard Group Inc. Buys 13,133 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Vanguard Group Inc. increased its stake in Supernus Pharmaceuticals by 0.2%, acquiring 13,133 additional shares, bringing their total ownership to 6,163,892 shares, valued at approximately $201.87 million.
• Several institutional investors have significantly increased their holdings in Supernus, with Woodline Partners LP growing its stake by 124.8% during the last quarter.
• Supernus Pharmaceuticals received a rating upgrade from Wall Street analysts, with Cantor Fitzgerald raising the target price from $42 to $46 and a consensus rating of "Moderate Buy."

Vanguard Group Inc. boosted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 0.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,163,892 shares of the specialty pharmaceutical company's stock after acquiring an additional 13,133 shares during the quarter. Vanguard Group Inc. owned 11.01% of Supernus Pharmaceuticals worth $201,867,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Woodline Partners LP grew its holdings in shares of Supernus Pharmaceuticals by 124.8% in the 4th quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company's stock worth $15,326,000 after purchasing an additional 235,257 shares during the last quarter. BNP Paribas Financial Markets grew its stake in Supernus Pharmaceuticals by 248.0% during the fourth quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company's stock worth $10,581,000 after buying an additional 208,552 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $6,847,000. GW&K Investment Management LLC increased its holdings in shares of Supernus Pharmaceuticals by 14.6% during the first quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company's stock worth $45,275,000 after buying an additional 176,091 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. raised its stake in shares of Supernus Pharmaceuticals by 33.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 545,658 shares of the specialty pharmaceutical company's stock valued at $19,731,000 after acquiring an additional 136,870 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Wall Street Zen upgraded Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Cantor Fitzgerald increased their target price on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Supernus Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $41.00.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock opened at $42.00 on Wednesday. The firm's 50 day moving average price is $34.75 and its two-hundred day moving average price is $33.59. Supernus Pharmaceuticals, Inc. has a 52-week low of $29.16 and a 52-week high of $43.73. The stock has a market cap of $2.35 billion, a PE ratio of 36.52 and a beta of 0.74.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, Director Frederick M. Hudson sold 7,457 shares of the firm's stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $42.26, for a total transaction of $315,132.82. Following the transaction, the director owned 46,307 shares in the company, valued at approximately $1,956,933.82. This trade represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bethany Sensenig sold 5,369 shares of the company's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $42.25, for a total value of $226,840.25. The disclosure for this sale can be found here. Insiders sold a total of 152,826 shares of company stock valued at $6,424,773 over the last three months. Company insiders own 8.80% of the company's stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.